Liquid Biopsy Approaches for Cancer Characterization, Residual Disease Detection, and Therapy Monitoring [0.03%]
液体活检在癌症表征、残余疾病检测和治疗监测中的应用
Jacqueline V Aredo,Amna Jamali,Jessica Zhu et al.
Jacqueline V Aredo et al.
Liquid biopsy encompasses a variety of molecular approaches to detect circulating tumor DNA (ctDNA) and has become a powerful tool in the diagnosis and treatment of solid tumors. Current applications include comprehensive genomic profiling ...
Melvin L K Chua,Xin Zhang,Kenneth C W Wong et al.
Melvin L K Chua et al.
Easy as ABC: Managing Toxicities of Antibody-Drug Conjugates, Bispecific Antibodies, and CAR T-Cell Therapies [0.03%]
ABC简单术：抗体偶联药物、双特异性抗体和CAR-T细胞治疗毒性管理
Michael D Jain,Jeremy S Abramson,Stephen M Ansell
Michael D Jain
Antibody-drug conjugates (ADCs), bispecific antibodies that engage T cells (BsAbs), and chimeric antigen receptor (CAR) T cells are widely used standard-of-care therapies that have revolutionized the treatment of lymphoid and plasma cell ma...
Carsten U Niemann,Abraham Varghese,Talha Munir et al.
Carsten U Niemann et al.
Chronic lymphocytic leukemia (CLL) remains an incurable disease, except in rare cases treated with allogeneic stem-cell transplantation or favorable-risk CLL treated with chemoimmunotherapy. Treatment initiation follows the Rai and Binet st...
Which Is the Best Tyrosine Kinase Inhibitor for Newly Diagnosed Chronic Myelogenous Leukemia? [0.03%]
新诊断的慢性髓性白血病的最佳酪氨酸激酶抑制剂是什么？
Naranie Shanmuganathan,Michael Osborn,Timothy P Hughes
Naranie Shanmuganathan
The choice of frontline therapy for a patient with chronic phase chronic myeloid leukemia (CP-CML) can have a profound effect on the long-term clinical outcome. Currently, five tyrosine kinase inhibitors (TKIs-imatinib, dasatinib, nilotinib...
Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship [0.03%]
肿瘤免疫治疗中的肠道微生物菌群：抗生素管理的医学肿瘤学实用指南
Arielle Elkrief,Bertrand Routy,Lisa Derosa et al.
Arielle Elkrief et al.
The gut microbiota has emerged as a critical determinant of immune checkpoint inhibitor (ICI) efficacy, resistance, and toxicity. Retrospective and prospective studies profiling the taxonomic composition of intestinal microbes of patients t...
Multicancer Early Detection Tests at a Crossroads: Commercial Availability Ahead of Definitive Evidence [0.03%]
多癌早期检测试验的关键路口：在缺乏决定性证据的情况下推出商业产品
Carmen E Guerra,Jennifer Keating Litton,Carolina E Viswanath et al.
Carmen E Guerra et al.
Multicancer early detection tests (MCEDs), sometimes referred to as liquid biopsies, are tests that can screen for multiple cancers by analyzing blood, urine, and other bodily fluids for biomarkers released by cancer cells. These tests have...
Empowering the Next Generation of Cancer Research Advocates: Community Engagement Across the Research Continuum [0.03%]
赋能下一代癌症研究倡导者：贯穿研究全程的社区参与
Melissa Mazor,Sarah Miller,Sarah Mollman et al.
Melissa Mazor et al.
Community engagement represents a foundational strategy for advancing cancer research and improving health outcomes. This study examines advocacy as a form of community engagement across the cancer research continuum, aligning with ASCO's 2...
Urvashi Mitbander Joshi,Jasmin Hundal,Jonaphine R Mata et al.
Urvashi Mitbander Joshi et al.
Combination immune checkpoint inhibitor therapy (ICI) with ipilimumab (anti-cytotoxic T-lymphocyte-associated protein 4) + nivolumab (anti-PD-1) in untreated, metastatic melanoma has achieved a ten-year melanoma-specific survival of 52%. Ho...
Designing Clinical Trials for Patients With Rare Cancers: Connecting the Zebras [0.03%]
罕见癌症患者的临床试验设计：连接斑马们
Vivek Subbiah,Megan Othus,Jim Palma et al.
Vivek Subbiah et al.
The field of rare cancer research is rapidly transforming, marked by significant progress in clinical trials and treatment strategies. Rare cancers, as defined by the National Cancer Institute, occur in fewer than 150 cases per million peop...